ReviewClinical reviews in allergy & immunology2011
Urinary biomarkers in lupus nephritis.
Review in Clinical reviews in allergy & immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Renal failure · 2021Pooled it
- Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis.Medicine · 2017Pooled it
- Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review.Journal of cellular and molecular medicine · 2017Pooled it
- Article
- Smith-specific regulatory T cells halt the progression of lupus nephritis.Nature communications · 2024Article
- V-Set Immunoglobulin Domain-Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus.Lupus science & medicine · 2022Article
- Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications.Frontiers in immunology · 2022Review
- The promising role and prognostic value of miR-198 in human diseases.American journal of translational research · 2022Article
- Analysis of TNF-like weak inducer of apoptosis for detecting lupus nephritis.Comparative clinical pathology · 2022Article
- Article
- The Most Promising Biomarkers of Allogeneic Kidney Transplant Rejection.Journal of immunology research · 2022Review
- Predicting lupus membranous nephritis using reduced picolinic acid to tryptophan ratio as a urinary biomarker.iScience · 2021Article
- Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa.International urology and nephrology · 2021Observational
- Circulating Free DNA and Its Emerging Role in Autoimmune Diseases.Journal of personalized medicine · 2021Review
- Management of Lupus Nephritis.Journal of clinical medicine · 2021Review
- Acute skin exposure to ultraviolet light triggers neutrophil-mediated kidney inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis.BMC rheumatology · 2020Article
- ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2020Article
- Clinical and histological significance of urinary CD11cArthritis research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Renal involvement in patients with systemic lupus erythematosus in the form of severe lupus nephritis is associated with a significant burden of morbidity and mortality. Conventional laboratory biomarkers in current use have not been very successful in anticipating disease flares, predicting renal histology, or decreasing unwanted outcomes. Since early treatment is associated with improved clinical results, it is thus essential to identify new biomarkers with substantial predictive power to reduce the serious sequelae of this difficult to control lupus manifestation. Indeed, considerable efforts and progress have been made over the last few years in the search for novel biomarkers. Since urinary biomarkers are more easily obtainable with much less risk to the patient than repeat renal biopsies, and these may more accurately discern between renal disease and other organ manifestations than their serum counterparts, there has been tremendous interest in studying new candidate urine biomarkers. Below, we review several promising urinary biomarkers under investigation, including total proteinuria and microalbuminuria, urinary proteomic signatures, and the individual inflammatory mediators interleukin-6, vascular cell adhesion molecule-1, CXCL16, IP-10, and tumor necrosis factor-like weak inducer of apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.